Almac Releases ePRO Data
Almac announced the results of a survey conducted by researchers at the Tufts Center for the Study of Drug Development.
Almac Group, a global provider of technology and services for the pharmaceutical and biotech industries announced the results of a survey conducted by researchers at the Tufts Center for the Study of Drug Development, which was backed by a grant from Almac. The survey found that sponsor and CRO companies are receptive to, and plan to increase their use of ePRO. The results revealed that the top benefits of ePRO adoption are increased data quality, patient compliance, and efficiency of data collection.
The results of the survey, http://www.almacgroup.com/wp-content/uploads/Tufts-CSDD-Study-of-ePRO-Usage-in-Clinical-Trials.pdf based on 22 responses from 18 companies, also show that the adoption rate of ePRO will continue to rise, as it is still a relatively new addition to clinical research programs. More than two-fifths (61%) of respondents indicated their companies began using ePRO in the last five years, while 11% have been using ePRO for more than 10 years. In examining future trends, more than three-quarters of respondents expected that there would be increasing ePRO usage for post-marketing trials for primary and secondary endpoints.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
